S&P 500   4,145.19
DOW   32,803.47
QQQ   321.75
China July exports rise, with trade surplus at record-high
Shift in war's front seen as ships cleared to leave Ukraine
What's in Democrats' big bill? Climate, health care, savings
Demand for grocery delivery cools as food costs rise
Transit woes mount for Boston's beleaguered subway riders
What to Expect from the Markets in a Recession
Dems push Biden climate, health priorities toward Senate OK
S&P 500   4,145.19
DOW   32,803.47
QQQ   321.75
China July exports rise, with trade surplus at record-high
Shift in war's front seen as ships cleared to leave Ukraine
What's in Democrats' big bill? Climate, health care, savings
Demand for grocery delivery cools as food costs rise
Transit woes mount for Boston's beleaguered subway riders
What to Expect from the Markets in a Recession
Dems push Biden climate, health priorities toward Senate OK
S&P 500   4,145.19
DOW   32,803.47
QQQ   321.75
China July exports rise, with trade surplus at record-high
Shift in war's front seen as ships cleared to leave Ukraine
What's in Democrats' big bill? Climate, health care, savings
Demand for grocery delivery cools as food costs rise
Transit woes mount for Boston's beleaguered subway riders
What to Expect from the Markets in a Recession
Dems push Biden climate, health priorities toward Senate OK
S&P 500   4,145.19
DOW   32,803.47
QQQ   321.75
China July exports rise, with trade surplus at record-high
Shift in war's front seen as ships cleared to leave Ukraine
What's in Democrats' big bill? Climate, health care, savings
Demand for grocery delivery cools as food costs rise
Transit woes mount for Boston's beleaguered subway riders
What to Expect from the Markets in a Recession
Dems push Biden climate, health priorities toward Senate OK
LON:HCM

HUTCHMED - HCM Share Forecast, Price & News

GBX 220
+12.50 (+6.02%)
(As of 08/5/2022 07:38 PM ET)
Add
Compare
Today's Range
215.71
230
50-Day Range
156.80
252
52-Week Range
137.80
621
Volume
240,393 shs
Average Volume
117,409 shs
Market Capitalization
£1.90 billion
P/E Ratio
N/A
Dividend Yield
N/A
Price Target
GBX 160

HUTCHMED MarketRank™ Forecast

Analyst Rating
Moderate Buy
2.50 Rating Score
Upside/​Downside
27.3% Downside
GBX 160 Price Target
Short Interest
N/A
Dividend Strength
N/A
Sustainability
N/A
News Sentiment
0.00mentions of HUTCHMED in the last 14 days
Based on 3 Articles This Week
Insider Trading
N/A
Proj. Earnings Growth
N/A

Overall MarketRank

MarketRank is calculated as an average of available category scores, with extra weight given to analysis and valuation.

0.62 out of 5 stars

HCM stock logo

About HUTCHMED (LON:HCM) Stock

HUTCHMED (China) Limited discovers, develops, and commercializes targeted therapeutics and immunotherapies for cancer and immunological diseases in HongKong and internationally. It operates in Oncology/Immunology and Other Ventures segments. The company develops Savolitinib, an inhibitor for non-small cell lung cancer (NSCLC), papillary and renal cell carcinoma, colorectal cancer (CRC), and gastric cancer (GC); and Fruquintinib, an inhibitor for CRC, breast cancer, GC, endometrial cancer (EMC), NSCLC, hepatocellular carcinoma, and gastrointestinal and solid tumors. It also develops Surufatinib, an inhibitor for neuroendocrine tumors (NET), pancreatic NET, non-pancreatic NET, biliary tract cancer, sarcoma, neuroendocrine neoplasm, esophageal cancer, small cell lung cancer, GC, thyroid cancer, EMC, NSCLC, and solid tumors; HMPL-523, a spleen tyrosine kinase inhibitor for hematological cancers and certain chronic immune diseases; and HMPL-689 for isoform PI3Kd (phosphoinositide 3'-kinase delta). In addition, it develops Tazemetostat, an inhibitor of EZH2 for the treatment of certain epithelioid sarcoma and follicular lymphoma patients; HMPL-306, an inhibitor for hematological malignancies, gliomas, and solid tumors; HMPL-760, an Bruton's tyrosine kinase inhibitor; HMPL-453, an inhibitor for intrahepatic cholangiocarcinoma; HMPL-295 for solid tumors; HMPL-653 for metastatic solid tumors and tenosynovial giant cell tumors; and Epitinib (HMPL-813) and Theliatinib (HMPL-309) inhibitors. It has collaboration agreements with AstraZeneca AB (publ), Lilly (Shanghai) Management Company Limited, BeiGene, Inmagene Biopharmaceuticals Co. Ltd., Innovent Biologics Co., Inc., Genor Biopharma Co. Ltd., Shanghai Junshi Biosciences Co. Ltd., and Epizyme, Inc. The company was formerly known as Hutchison China MediTech Limited and changed its name to HUTCHMED (China) Limited in May 2021. The company was incorporated in 2000 and is headquartered in Central, Hong Kong.

Analyst Upgrades and Downgrades

HCM has been the topic of a number of recent analyst reports. Citigroup reiterated a "buy" rating and issued a GBX 220 ($2.70) price objective on shares of HUTCHMED in a report on Thursday, June 23rd. Barclays restated an "equal weight" rating and issued a GBX 100 ($1.23) target price on shares of HUTCHMED in a research note on Tuesday, July 19th.

HUTCHMED Stock Performance

Shares of LON:HCM traded up GBX 12.50 ($0.15) during trading on Friday, reaching GBX 220 ($2.70). 240,391 shares of the company's stock traded hands, compared to its average volume of 117,409. The company has a debt-to-equity ratio of 3.75, a current ratio of 3.89 and a quick ratio of 3.73. HUTCHMED has a 12 month low of GBX 137.80 ($1.69) and a 12 month high of GBX 621 ($7.61). The company has a 50 day moving average of GBX 201.39 and a 200-day moving average of GBX 263.79. The stock has a market capitalization of £1.90 billion and a P/E ratio of -10.95.

Receive HCM Stock News and Ratings via Email

Sign-up to receive the latest news and ratings for HUTCHMED and its competitors with MarketBeat's FREE daily newsletter.

HCM Stock News Headlines

HUTCHMED (LON:HCM) Earns Equal Weight Rating from Barclays
Which way now for the HUTCHMED (China) share price?
Appointment of Non–Executive Director
See More Headlines
Receive HCM Stock News and Ratings via Email

Sign-up to receive the latest news and ratings for HUTCHMED and its competitors with MarketBeat's FREE daily newsletter.

Industry, Sector and Symbol

Industry
Drug Manufacturers - Major
Sub-Industry
N/A
CIK
N/A
Fax
N/A
Employees
1,760
Year Founded
N/A

Price Target and Rating

Average Stock Price Forecast
GBX 160
High Stock Price Forecast
GBX 220
Low Stock Price Forecast
GBX 100
Forecasted Upside/Downside
-27.3%
Consensus Rating
Moderate Buy
Rating Score (0-4)
2.50
Research Coverage
2 Analysts

Profitability

Pretax Margin
N/A

Debt

Sales & Book Value

Annual Sales
£356.13 million
Cash Flow
GBX 122.39 per share
Book Value
GBX 115.20 per share

Miscellaneous

Free Float
N/A
Market Cap
£1.90 billion
Optionable
Not Optionable
Beta
N/A

Key Executives

  • Mr. Chi Keung To ACGI (Age 70)
    B.Sc., BSc, M.B.A., MBA, Exec. Chairman
    Comp: $85k
  • Dr. Weiguo Su B.Sc. (Age 65)
    Ph.D., CEO, Chief Scientific Officer & Exec. Director
    Comp: $1.36M
  • Mr. Chig Fung Cheng BEc (Age 55)
    CA, CFO & Exec. Director
    Comp: $838.51k
  • Ms. Edith Shih C.S. (Age 70)
    CGP, FCS, M.A., P.E., BSE, EdM, Solicito, Company Sec. & Non-Exec. Director
    Comp: $74.3k
  • Dr. Karen Jane Atkin (Age 56)
    Exec. VP & COO
  • Mr. Kin Hung Lee M.B.A. (Age 45)
    Sr. VP of Corp. Fin. & Devel.
  • Mr. Charles George Rupert Nixon (Age 52)
    Group Gen. Counsel
  • Ms. Selina Zhang
    Sr. VP of Global HR
  • Dr. Qingmei Wang Ph.D. (Age 59)
    Sr. VP of Bus. Devel. & Strategic Alliances
  • Mr. Hong Chen (Age 52)
    Sr. VP & Chief Commercial Officer- China













HCM Stock - Frequently Asked Questions

Should I buy or sell HUTCHMED stock right now?

2 Wall Street research analysts have issued "buy," "hold," and "sell" ratings for HUTCHMED in the last twelve months. There are currently 1 hold rating and 1 buy rating for the stock. The consensus among Wall Street research analysts is that investors should "buy" HUTCHMED stock.
View analyst ratings for HUTCHMED
or view top-rated stocks.

What is HUTCHMED's stock price forecast for 2022?

2 brokers have issued 12-month price targets for HUTCHMED's stock. Their HCM stock forecasts range from GBX 100 to GBX 220. On average, they expect HUTCHMED's share price to reach GBX 160 in the next year. This suggests that the stock has a possible downside of 27.3%.
View analysts' price targets for HUTCHMED
or view top-rated stocks among Wall Street analysts.

How has HUTCHMED's stock price performed in 2022?

HUTCHMED's stock was trading at GBX 530 at the beginning of 2022. Since then, HCM stock has decreased by 58.5% and is now trading at GBX 220.
View the best growth stocks for 2022 here
.

What other stocks do shareholders of HUTCHMED own?

Based on aggregate information from My MarketBeat watchlists, some companies that other HUTCHMED investors own include Intelsat (I), Associated British Foods (ABF), Fossil Group (FOSL), Chaarat Gold (CGH), AMC Entertainment (AMC), Bank of America (BAC), First Data (FDC), Air Canada (AC), Apollo Global Management (APO) and China Unicom (Hong Kong) (CHU).

What is HUTCHMED's stock symbol?

HUTCHMED trades on the London Stock Exchange (LON) under the ticker symbol "HCM."

How do I buy shares of HUTCHMED?

Shares of HCM stock and other U.K. stocks can be purchased through online brokerage accounts that support trading on the London Stock Exchange (LSX). Some U.K. companies can be purchased through major U.S. brokerages in the form of American Depository Receipts (ADRs), which are placeholder equities held in a trust by a bank that represent shares of a foreign stock.
Compare Top Brokerages Here.

What is HUTCHMED's stock price today?

One share of HCM stock can currently be purchased for approximately GBX 220.

How much money does HUTCHMED make?

HUTCHMED (LON:HCM) has a market capitalization of £1.90 billion and generates £356.13 million in revenue each year.

How many employees does HUTCHMED have?

HUTCHMED employs 1,760 workers across the globe.

How can I contact HUTCHMED?

The official website for HUTCHMED is www.chi-med.com. The company can be reached via phone at +85221213888.

This page (LON:HCM) was last updated on 8/8/2022 by MarketBeat.com Staff

MarketBeat Resources

Premium Research Tools

MarketBeat All Access subscribers can access stock screeners, the Idea Engine, data export tools, research reports, and other premium tools.

Discover All Access

Market Data and Calendars

Looking for new stock ideas? Want to see which stocks are moving? View our full suite of financial calendars and market data tables, all for free.

View Market Data

Investing Education and Resources

Receive a free world-class investing education from MarketBeat. Learn about financial terms, types of investments, trading strategies and more.

Financial Terms
Details Here
MarketBeat - Stock Market News and Research Tools logo

MarketBeat empowers individual investors to make better trading decisions by providing real-time financial data and objective market analysis. Whether you’re looking for analyst ratings, corporate buybacks, dividends, earnings, economic reports, financials, insider trades, IPOs, SEC filings or stock splits, MarketBeat has the objective information you need to analyze any stock. Learn more about MarketBeat.

MarketBeat is accredited by the Better Business Bureau MarketBeat is rated as Great on TrustPilot

© American Consumer News, LLC dba MarketBeat® 2010-2022. All rights reserved.
326 E 8th St #105, Sioux Falls, SD 57103 | contact@marketbeat.com | (844) 978-6257
MarketBeat does not provide personalized financial advice and does not issue recommendations or offers to buy stock or sell any security.

Our Accessibility Statement | Terms of Service | Privacy Policy | Do Not Sell My Information | RSS Feeds

© 2022 Market data provided is at least 10-minutes delayed and hosted by Barchart Solutions. Information is provided 'as-is' and solely for informational purposes, not for trading purposes or advice, and is delayed. To see all exchange delays and terms of use please see Barchart's disclaimer.